Drug‐induced peripheral oedema: An aetiology‐based review

Largeau, Bérenger; Cracowski, Jean‐Luc; Lengelle, Céline; Sautenet, Bénédicte; Jonville‐Béra, Annie‐Pierre

doi:10.1111/bcp.14752

Cited by 30 publications

(43 citation statements)

References 147 publications

(323 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Permeability edema occurs mainly in the lower legs. 7 In the case reported here, the patient was unable to wear shoes due to edema and unable to ride a bicycle due to dorsiflexion. This was a major hindrance to his daily life.…”

Section: Discussionmentioning

confidence: 76%

“…6 Drug-induced peripheral edema has been described as noninflammatory edema and has four mechanisms: precapillary arteriolar vasodilation (vasodilatory edema), sodium/water retention (renal edema), lymphatic insufficiency (lymphedema) and increased capillary permeability (permeability edema). 7 The etiology of MET inhibitor-induced edema is still unclear, but may be attributable to an attenuation of HGF-mediated signaling in the peripheral vascular endothelium. 1,6 In physiological conditions, HGF in the vascular endothelium helps to protect against VEGF-induced endothelial hyperpermeability.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

et al. 2021

View full text Add to dashboard Cite

In May 2020 and February 2021, capmatinib and tepotinib, respectively were approved by the Food and Drug Administration (FDA) for the treatment of metastatic non-small cell lung carcinoma harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations. Herein, we present a case of intolerable peripheral edema caused by tepotinib, in which MET inhibitor could be continued by switching to capmatinib. Peripheral edema has been identified as one of the most common adverse events in capmatinib and tepotinib; however, there is no unified management for this adverse event. This is the first report that two MET inhibitors have different effects on the development of peripheral edema, and that the MET inhibitors can be continued by switching these drugs.

show abstract

Section: Discussionmentioning

confidence: 76%

Section: Discussionmentioning

confidence: 99%

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Future research should investigate the causal direction of the relationships identified in this study. In addition, we did not investigate the distribution of potential causes of edema (e.g., heart failure [ 3 ] or medication usage [ 4 ]) in this cohort, which could provide important information regarding allocation of resources to treat edema. A single self-report question was used to identify peripheral edema.…”

Section: Discussionmentioning

confidence: 99%

“…Chronic edema of the lower limbs (i.e., chronic peripheral edema) can cause pain, heaviness, weakness, discomfort, and negative body image, and limitations in mobility and flexibility [ 1 ]. Multiple causes of peripheral edema exist, including deficiencies in the venous or lymphatic systems [ 2 ], heart failure [ 3 ], and certain medications [ 4 ]. When peripheral edema is untreated, it can increase the risk of infection and ulcers [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Peripheral edema: A common and persistent health problem for older Americans

et al. 2021

View full text Add to dashboard Cite

Peripheral edema (i.e., lower limb swelling) can cause pain, weakness, and limited range of motion. However, few studies have examined its prevalence in the U.S. or its association with demographics, comorbidities, activity, or mobility. This study used data from the Health and Retirement Study, a nationally representative longitudinal survey of U.S. adults (age 51+/ N = 19,988 for 2016), to evaluate time trends and correlates of peripheral edema using weighted descriptive statistics and logistic regressions, respectively. Peripheral edema was assessed with the question “Have you had… // Persistent swelling in your feet or ankles?” The weighted prevalence of edema among older U.S. adults was 19% to 20% between 2000 and 2016. Peripheral edema was associated with older age, female sex, non-white race, low wealth, obesity, diabetes, hypertension, pain, low activity levels, and mobility limitations (odds ratios ranging from 1.2–5.6; p-values ≤0.001). This study provides the first estimates of national prevalence and correlates of peripheral edema among older Americans. Peripheral edema is common and strongly associated with comorbidities, pain, low activity levels, and mobility limitations, and disproportionately affects poorer and minority groups. Peripheral edema should be a focus of future research in order to develop novel and cost-effective interventions.

show abstract

“…Medication use may also cause or worsen peripheral edema [ 26 ]. Some vasodilators, such as calcium channel blockers, may cause an increase in capillary hydrostatic pressure, which results in extravasation of fluid to the interstitium and edema [ 27 , 28 ].…”

Section: Edema From a Clinical Perspectivementioning

confidence: 99%

Clinical Perspectives and Management of Edema in Chronic Venous Disease—What about Ruscus?

Bihari

Guex²,

Jawień

et al. 2022

Medicines

View full text Add to dashboard Cite

Background: Edema is highly prevalent in patients with cardiovascular disease and is associated with various underlying pathologic conditions, making it challenging for physicians to diagnose and manage. Methods: We report on presentations from a virtual symposium at the Annual Meeting of the European Venous Forum (25 June 2021), which examined edema classification within clinical practice, provided guidance on making differential diagnoses and reviewed evidence for the use of the treatment combination of Ruscus extract, hesperidin methyl chalcone and vitamin C. Results: The understanding of the pathophysiologic mechanisms underlying fluid build-up in chronic venous disease (CVD) is limited. Despite amendments to the classic Starling Principle, discrepancies exist between the theories proposed and real-world evidence. Given the varied disease presentations seen in edema patients, thorough clinical examinations are recommended in order to make a differential diagnosis. The recent CEAP classification update states that edema should be considered a sign of CVD. The combination of Ruscus extract, hesperidin methyl chalcone and vitamin C improves venous tone and lymph contractility and reduces macromolecule permeability and inflammation. Conclusions: Data from randomized controlled trials support guideline recommendations for the use of Ruscus extract, hesperidin methyl chalcone and vitamin C to relieve major CVD-related symptoms and edema.

show abstract

Drug‐induced peripheral oedema: An aetiology‐based review

Abstract: Many drugs are responsible, through different mechanisms, for peripheral oedema.

Cited by 30 publications

References 147 publications

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema

Peripheral edema: A common and persistent health problem for older Americans

Clinical Perspectives and Management of Edema in Chronic Venous Disease—What about Ruscus?

Contact Info

Product

Resources

About